These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20687887)

  • 1. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
    Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
    Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of adverse effects due to antiretroviral drugs.
    Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
    AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis].
    Gutiérrez Maciá MM; Mateo García MG; Vidal Marsal F; Domingo Pedrol P
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():18-23. PubMed ID: 18680692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment.
    Giralt M; Díaz-Delfín J; Gallego-Escuredo JM; Villarroya J; Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3371-8. PubMed ID: 20687888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic toxicities of antiretroviral therapy.
    Herman JS; Easterbrook PJ
    Int J STD AIDS; 2001 Sep; 12(9):555-62; quiz 563-4. PubMed ID: 11516363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targets of metabolic toxicity of HIV antiretroviral drugs: the multiple roads to lipodystrophy and metabolic syndrome.
    Domingo P; Villarroya F
    Curr Pharm Des; 2010 Oct; 16(30):3337-8. PubMed ID: 20687885
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
    Barbaro G
    Curr HIV Res; 2006 Jan; 4(1):79-85. PubMed ID: 16454713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic disturbances associated with HAART].
    Olczak A
    Przegl Epidemiol; 2007; 61(4):639-46. PubMed ID: 18572495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
    Moyle G; Carr A
    HIV Clin Trials; 2002; 3(1):89-98. PubMed ID: 11894812
    [No Abstract]   [Full Text] [Related]  

  • 12. [Metabolic changes in HIV infected patient].
    Castelo Filho A; Abrão P
    Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):5-7. PubMed ID: 17435849
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
    Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
    Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients.
    Stankov MV; Behrens GM
    Curr Pharm Des; 2010 Oct; 16(30):3361-71. PubMed ID: 20687889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation.
    Feeney ER; Mallon PW
    Curr Pharm Des; 2010 Oct; 16(30):3339-51. PubMed ID: 20687890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the metabolic effects of HIV and HIV drugs.
    Brown TT; Glesby MJ
    Nat Rev Endocrinol; 2011 Sep; 8(1):11-21. PubMed ID: 21931374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients.
    Srinivasa S; Grinspoon SK
    Eur J Endocrinol; 2014 May; 170(5):R185-202. PubMed ID: 24523497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.